Silent Rectal Infections Are Reshaping the Global Fight Against Sexually Transmitted Diseases
Anorectal sexually transmitted infections are emerging as an increasingly important global health challenge, even as testing becomes more widely available. A new review in Nature Reviews Gastroenterology & Hepatology examines how infections caused primarily by Chlamydia trachomatis, Neisseria gonorrhoeae and Treponema pallidum are spreading, persisting and evading detection. The analysis describes a troubling paradox: improved molecular diagnostics can identify more infections than ever before, yet many cases remain undiagnosed because they produce no noticeable symptoms.
The burden is especially pronounced among men who have sex with men, a population in which anorectal infections can be more common than infections of the urethra. Rectal chlamydia, gonorrhoea and syphilis may occur without pain, discharge, bleeding or other signs that would prompt a person to seek medical care. This silent pattern allows infections to persist and increases the likelihood of onward transmission. It also means that testing based only on urine or genital samples can miss infections located exclusively in the rectum.
The biological environment of the anorectal tract helps explain why these infections can remain hidden. The rectum contains a complex epithelial surface, a dense microbial community and an immune system adapted to tolerate constant exposure to foreign substances. Bacteria that colonize this tissue can interact with epithelial cells, mucus and local immune defenses in ways that differ from infections at urogenital sites. According to the review, pathogen adaptation and relatively attenuated local inflammatory responses may prevent immune activity from reaching the threshold required to cause recognizable symptoms, even while bacterial replication and transmission continue.
Chlamydia illustrates the complexity of this process. The organism has a distinctive intracellular life cycle, entering epithelial cells and alternating between infectious elementary bodies and replicative reticulate bodies. Within rectal tissue, this cycle can support persistent infection while limiting the immediate inflammatory signals that would otherwise produce symptoms. Gonorrhoea, by contrast, is caused by a bacterium capable of rapid genetic adaptation, including changes in surface proteins and mechanisms that help it evade immune recognition. These adaptations contribute to repeated infections and complicate the development of durable immunity.
Syphilis adds another layer of difficulty because its causative organism, T. pallidum, can disseminate beyond the initial site of infection. Rectal exposure may produce lesions that are internal, painless or difficult to observe, allowing infection to progress unnoticed. Without diagnosis and treatment, syphilis can move through distinct clinical stages and eventually affect multiple organ systems. The overlap between asymptomatic anorectal infection and broader systemic disease makes targeted screening essential, particularly for people with ongoing exposure risks or previous sexually transmitted infections.
Modern nucleic acid amplification tests have transformed the detection of anorectal infections. These assays identify pathogen-specific genetic material from rectal swabs and can detect infections that conventional culture or symptom-based evaluation would miss. Their high analytical sensitivity has expanded the known burden of disease and enabled more effective screening programs. However, molecular detection also creates an important interpretive problem: the presence of bacterial DNA or RNA does not always prove that viable, transmissible organisms remain. Genetic material may persist after treatment or after bacterial death, making it difficult to distinguish active infection from residual signals.
The review also emphasizes that access to testing remains uneven. Laboratory-based molecular assays may require trained personnel, specialized equipment and transport systems that are unavailable in many settings. Point-of-care tests could shorten the time between sampling, diagnosis and treatment, reducing loss to follow-up and limiting transmission. Yet such technologies must achieve sufficient sensitivity and specificity for anorectal specimens, where bacterial loads, sampling quality and mixed infections can vary. Faster diagnosis must also be paired with clear clinical guidance to prevent unnecessary antibiotic use.
Treatment is becoming more complicated as antimicrobial resistance advances, most notably in gonorrhoea. N. gonorrhoeae has acquired resistance to multiple antibiotic classes through genetic mutations, mobile genetic elements and mechanisms that reduce drug penetration or actively expel antibiotics from the cell. This narrowing therapeutic window increases the importance of culture and susceptibility testing when treatment failure is suspected. It also reinforces the need for surveillance systems that can detect resistance trends before they become widespread and for stewardship strategies that preserve the effectiveness of remaining therapies.
Prevention research is developing alongside new diagnostic and treatment approaches. Doxycycline post-exposure prophylaxis, commonly known as doxy-PEP, has been shown to substantially reduce the incidence of chlamydia and syphilis in selected populations when taken after sex under medical guidance. Its impact on gonorrhoea is less consistent, in part because resistance to tetracycline-class antibiotics is already common in many gonococcal strains. The broader use of doxy-PEP therefore requires careful monitoring for antimicrobial resistance, changes in the microbiome and possible effects on other bacterial infections.
Artificial intelligence may also contribute to future control strategies by helping identify people most likely to benefit from screening, interpreting clinical and laboratory data, and improving public-health surveillance. However, algorithms depend on the quality and representativeness of the data used to train them. Systems developed from narrowly defined clinical populations may perform poorly in communities with different epidemiological patterns, access to care or testing behaviors. The review concludes that controlling anorectal sexually transmitted infections will require more than advanced technology: it will depend on integrated screening, accessible care, responsible antibiotic use and research that reflects the diversity of real-world sexual health settings.
Subject of Research: Anorectal bacterial sexually transmitted infections, including chlamydia, gonorrhoea and syphilis; their epidemiology, pathogenesis, diagnosis, treatment and prevention.
Article Title: Mechanisms, management and prevention of anorectal sexually transmitted infections
Article References: Latt, P.M., Kong, F.Y.S., Khosropour, C.M. et al. “Mechanisms, management and prevention of anorectal sexually transmitted infections.” Nature Reviews Gastroenterology & Hepatology (2026). https://doi.org/10.1038/s41575-026-01232-6
Image Credits: AI Generated
DOI: 10.1038/s41575-026-01232-6
Keywords: anorectal sexually transmitted infections, chlamydia, gonorrhoea, syphilis, men who have sex with men, molecular diagnostics, antimicrobial resistance, doxycycline post-exposure prophylaxis, artificial intelligence, sexual health
Tags: Anorectal sexually transmitted infectionsasymptomatic infection managementasymptomatic infectionshidden STI infectionsmolecular testing for STIsMSM sexual healthrectal chlamydiarectal gonorrhearectal syphilissexually transmitted disease diagnosticsSTI prevention strategiesSTI transmission in anorectal area
